Manus Bio, a global leader in the sustainable production of plant-based ingredients, announced today that Prof. Joe Chappell, a founder of Allylix and luminary in the areas of terpene synthase structure/function and natural products drug discovery, has joined the Manus Bio Scientific Advisory Board.
Chappell is currently a Professor and Chair of the University of Kentucky’s College of Pharmacy’s Department of Pharmaceutical Sciences. His research experiences have included positions at the University of Freiburg, the Max Planck Institute in Cologne, and the University of California at San Diego. In 2002, he co-founded Allylix, Inc, one of the first natural product biomanufacturing companies.
Chappell’s research has been dedicated to studying all facets of isoprenoid metabolism in plants. From the identification of the genes encoding for and regulating isoprenoid metabolism to defining the biochemical mechanisms of the enzymes themselves, Dr. Chappell has seen the field mature over the decades both in academia and industry. As Chair of the University of Kentucky’s Department of Pharmaceutical Sciences, he now leads collaborations in developing new plant-based therapeutic agents, creating strong synergies with Manus’ discovery and production platform.
Manus Bio Co-founder and Chief Technology Officer Dr. Ajikumar Parayil commented: “Joe Chappell is a highly respected scientist and industry leader whose deep knowledge, experience, and network will be hugely valuable to Manus Bio. We are thrilled to add a scientist of this caliber to our Scientific Advisory Board.”